Found: 1026
Select item for more details and to access through your institution.
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
- Published in:
- International Journal of Hematology, 2024, v. 120, n. 2, p. 203, doi. 10.1007/s12185-024-03787-z
- By:
- Publication type:
- Article
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3333, doi. 10.1002/cncr.35388
- By:
- Publication type:
- Article
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3344, doi. 10.1002/cncr.35384
- By:
- Publication type:
- Article
Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies.
- Published in:
- Annals of the New York Academy of Sciences, 2000, v. 922, n. 1, p. 247, doi. 10.1111/j.1749-6632.2000.tb07043.x
- By:
- Publication type:
- Article
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 4, p. 870, doi. 10.1007/s10637-015-0242-6
- By:
- Publication type:
- Article
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 6, p. 1206, doi. 10.1007/s10637-010-9465-8
- By:
- Publication type:
- Article
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 818, doi. 10.1007/s10637-010-9429-z
- By:
- Publication type:
- Article
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.
- Published in:
- 2011
- By:
- Publication type:
- Report
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 2, p. 323, doi. 10.1007/s10637-009-9369-7
- By:
- Publication type:
- Article
MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 402, doi. 10.1007/s10637-009-9267-z
- By:
- Publication type:
- Article
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
- Published in:
- Genes, Chromosomes & Cancer, 2010, v. 49, n. 2, p. 182, doi. 10.1002/gcc.20732
- By:
- Publication type:
- Article
Ponatinib‐review of historical development, current status, and future research.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1576, doi. 10.1002/ajh.27355
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1423, doi. 10.1002/ajh.27329
- By:
- Publication type:
- Article
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
- By:
- Publication type:
- Article
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 6, p. 1175, doi. 10.1002/ajh.27307
- By:
- Publication type:
- Article
Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 5, p. 836, doi. 10.1002/ajh.27254
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1780, doi. 10.1002/ajh.27070
- By:
- Publication type:
- Article
Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E281, doi. 10.1002/ajh.27043
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. 1619, doi. 10.1002/ajh.27037
- By:
- Publication type:
- Article
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. 1350, doi. 10.1002/ajh.27007
- By:
- Publication type:
- Article
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. 1383, doi. 10.1002/ajh.26997
- By:
- Publication type:
- Article
CD19‐negative relapse in adult patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia following treatment with blinatumomab‐a post hoc analysis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. E222, doi. 10.1002/ajh.26988
- By:
- Publication type:
- Article
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. 1196, doi. 10.1002/ajh.26949
- By:
- Publication type:
- Article
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 6, p. E142, doi. 10.1002/ajh.26907
- By:
- Publication type:
- Article
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 658, doi. 10.1002/ajh.26852
- By:
- Publication type:
- Article
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E91, doi. 10.1002/ajh.26858
- By:
- Publication type:
- Article
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 639, doi. 10.1002/ajh.26836
- By:
- Publication type:
- Article
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 493, doi. 10.1002/ajh.26816
- By:
- Publication type:
- Article
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. E53, doi. 10.1002/ajh.26811
- By:
- Publication type:
- Article
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. E11, doi. 10.1002/ajh.26622
- By:
- Publication type:
- Article
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1616, doi. 10.1002/ajh.26667
- By:
- Publication type:
- Article
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E422, doi. 10.1002/ajh.26707
- By:
- Publication type:
- Article
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1427, doi. 10.1002/ajh.26700
- By:
- Publication type:
- Article
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E416, doi. 10.1002/ajh.26692
- By:
- Publication type:
- Article
Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1443, doi. 10.1002/ajh.26694
- By:
- Publication type:
- Article
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1413, doi. 10.1002/ajh.26689
- By:
- Publication type:
- Article
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1419, doi. 10.1002/ajh.26686
- By:
- Publication type:
- Article
Real‐life incidence of thrombotic events in leukemia patients treated with ponatinib.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. E350, doi. 10.1002/ajh.26645
- By:
- Publication type:
- Article
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1236, doi. 10.1002/ajh.26642
- By:
- Publication type:
- Article
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>−4</sup> and higher.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1135, doi. 10.1002/ajh.26634
- By:
- Publication type:
- Article
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1005, doi. 10.1002/ajh.26595
- By:
- Publication type:
- Article
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 885, doi. 10.1002/ajh.26572
- By:
- Publication type:
- Article
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 856, doi. 10.1002/ajh.26550
- By:
- Publication type:
- Article
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 865, doi. 10.1002/ajh.26557
- By:
- Publication type:
- Article
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E201, doi. 10.1002/ajh.26526
- By:
- Publication type:
- Article
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 329, doi. 10.1002/ajh.26451
- By:
- Publication type:
- Article